Literature DB >> 7647401

OK-432 induces production of neutrophil chemotactic factors in malignant pleural effusion.

M Kataoka1, R Morishita, J Hiramatsu, H Ueoka, Y Nakata, T Ohnoshi, I Kimura, M Harada.   

Abstract

We investigated the changes in cellular components and neutrophil chemotactic factors in pleural fluid from 19 lung cancer patients who received intrapleural injection of OK-432 to treat malignant pleurisy. Not only neutrophil chemotactic activity (NCA) but also neutrophil count and percentage were increased significantly at 6 hours after OK-432 injection. The neutrophil count was significantly correlated with NCA level. The levels of C5a and IL-8 in pleural fluid were increased significantly after OK-432 injection. The increased IL-8 level was associated with a increase of both NCA and neutrophil count. OK-432 treatment also induced a marked increase of IL-1 beta and IL-6 in pleural fluid. Thus, intrapleural injection of OK-432 induced production of neutrophil chemotactic factors (IL-8 and C5a) and cytokines (IL-1 beta and IL-6), which eventually attracted neutrophils into the pleural space. These observations suggest that neutrophil migration mediated by these factors and cytokines may contribute to the sclerosing effects of OK-432 treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647401     DOI: 10.2169/internalmedicine.34.352

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

Review 1.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

2.  Novel approach to pleurodesis with 50 % glucose for air leakage after lung resection or pneumothorax.

Authors:  Kosuke Fujino; Yamato Motooka; Takamasa Koga; Hironobu Osumi; Eri Matsubara; Hidekatsu Shibata; Koei Ikeda; Kenji Shiraishi; Takeshi Mori; Koji Hayashi; Kentaro Yoshimoto; Jyoeji Wakimoto; Ichiro Kubota; Makoto Suzuki
Journal:  Surg Today       Date:  2015-07-24       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.